Financial Summary
January 1, 2020 - December 31, 2020
Third Quarter
January 1, 2020 - December 31, 2020
Third Quarter
Second Quarter
-
Consolidated Financial Summary Fiscal 2020 Interim (2,121KB)
-
Appendix to the Consolidated Financial Summary Fiscal 2020 Interim (573KB)
-
Results Presentation Fiscal 2020 Interim (735KB)
-
Summary of clinical trials (627KB)
-
Revenues from other products (22KB)
-
Transcript of Results Presentation Fiscal 2020 Interim (text) (1,274KB)
First Quarter
January 1, 2019 - December 31, 2019
Fiscal Year
-
Consolidated Financial Summary Fiscal 2019 (452KB)
-
Appendix to the Consolidated Financial Summary Fiscal 2019 (765KB)
-
Results Presentation Fiscal 2019 (1,045KB)
-
Summary of late-stage clinical trials (187KB)
-
Revenues from other products (23KB)
-
Transcript of Results Presentation Fiscal 2019 (text) (1,499KB)
Third Quarter
Second Quarter
-
Consolidated Financial Summary Fiscal 2019 Interim (251KB)
-
Appendix to the Consolidated Financial Summary Fiscal 2019 Interim (490KB)
-
Results Presentation Fiscal 2019 Interim (740KB)
-
Summary of late-stage clinical trials (227KB)
-
Revenues from other products (23KB)
-
Transcript of Results Presentation Fiscal 2019 Interim (text) (1,035KB)
First Quarter
IR Events
R&D Day
December 10, 2020
-
R&D Day Presentation (1,406KB)
-
Transcript (text) (2,871KB)
Updates on Nourianz marketing strategy in the U.S. and KW-6356 development
November 19, 2019
-
Agenda (101KB)
-
2019 US NOURIANZ Commercial Update (2,170KB)
-
A Phase 2a Study of KW-6356 in the Subjects with Parkinson's Disease (1,398KB)
-
Transcript (text) (2,086KB)
Update on KHK4083: A phase 1 study in subjects with atopic dermatitis
December 3, 2018
-
Agenda (78KB)
-
A phase 1 study of KHK4083 in subjects with atopic dermatitis (1,043KB)
Update on burosumab (KRN23): Clinical and regulatory updates, and pre-launch activities in the US and EU
October 27, 2017
IR News
-
October 30, 2020
Appendix to the Consolidated Financial Summary (IFRS) Fiscal 2020 Third Quarter
(605KB)
-
October 30, 2020
Consolidated Financial Summary (IFRS) Fiscal 2020 Third Quarter
(2,152KB)
-
July 30, 2020
Appendix to the Consolidated Financial Summary (IFRS) Fiscal 2020 Interim
(573KB)
-
July 30, 2020
Consolidated Financial Summary (IFRS) Fiscal 2020 Interim
(2,122KB)
-
May 01, 2020
Appendix to the Consolidated Financial Summary (IFRS) Fiscal 2020 First Quarter
(580KB)